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Sulfonate derived phosphoramidates as active 
intermediates in the enzymatic primer-extension of 
DNA 
S. De a, E. Groaz a, L. Margamuljana a, M. Abramov a, P. Marlière b and P. 
Herdewijn*a,b 
Novel  unnatural  5’‐phosphoramidate  nucleosides,  capable  of  being  processed  as  substrates  by  DNA 
polymerases for multiple nucleotide incorporations, have been designed. The mimics feature metabolites 
such as taurine and a broad range of aliphatic sulfonates coupled through a P‐N bond to the 5′‐phosphate 
position of deoxynucleotides, to allow binding interactions in the enzyme active site. The utility of all of 
the analogues as pyrophosphate mimics was demonstrated for the chain elongation of DNA, using both 
thermophilic and mesophilic microbial polymerases. 
 
 
 
 
 
 
 
 
INTRODUCTION 
In biological systems, phosphate esters and anhydrides are 
amongst the prevailing molecular fragments being released by 
metabolic transformations requiring good leaving groups, such 
as elimination and nucleophilic substitution reactions.1 For 
instance, DNA polymerization, the polynucleotide synthesis 
reaction, is an enzymatically-catalysed process, in which a free 
3′-hydroxyl nucleophilic group of a primer, base-paired to a 
DNA template, attacks the α-phosphate group of a nucleoside 
triphosphate with displacement and ensuing hydrolysis of 
pyrophosphate.2 This biochemical mechanism might have 
emerged during evolution as a result of either functional 
selection or synthetic accessibility.  
Our group has an ongoing program devoted to the diversification 
of nucleic acid metabolism by means of the systematic variation 
of both structural and enzymatic elements inherent to the genetic 
propagation of natural biopolymers.3 One important goal is the 
identification of novel components that, although not favored by 
natural selection, may nevertheless exist in nature and follow 
biochemical pathways orthogonal to natural ones. This may 
provide an opportunity to implement and propagate in vivo a 
third type of information carrier molecule (XNA), whilst 
succeeding in the establishment of both genetic and energetic 
enclaves.  
 
In the search for non-phosphate synthetic alternatives to 
pyrophosphate we have already demonstrated the leaving group 
properties of L-aspartic acid and other unnatural amino acids, in 
the DNA polymerase-catalyzed synthesis of DNA.4 This 
selection of substrates was partly motivated by the structural and 
electronic properties necessary to consent accommodation and 
recognition within the enzyme catalytic site, but most 
importantly by their significance as non-toxic intermediates of 
metabolic steps in living cells.  
In an extension of the substrate scope of the DNA polymerization 
reaction, we became interested in 5’-phosphoramidate 
deoxyribonucleoside analogues conserving the anionic residues 
for key binding interactions with polymerases in the form of 
aliphatic sulfonate-based functionalities.5 The design of such 
unnatural mimics of triphosphates is defined by the abundance 
of simple organic molecules such as taurine (2-
aminoethanesulfonic acid) and L-cysteic acid in natural 
environments and nutrients and their contribution as sources of 
mineral sulfur to microbial growth.6 Organic sulfonates are 
ionized at physiological pH with very low pKa values, thus their 
cellular uptake cannot occur by passive diffusion, but are rather 
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taken up across bacterial membranes by complex transport 
systems and actively degraded by the action of oxygenolytic 
enzymes over desulfonation pathways. Typically, this process 
releases sulfite as degradative intermediate, which then enters 
the sulphur assimilation cycle. This is one of the essential 
conditions that a good leaving group candidate must fulfil in 
order for nucleotide incorporation to be irreversible.  
It is well documented in the literature that under conditions of 
inorganic sulfate and cysteine starvation, various gene clusters 
are expressed in E. coli, allowing the alternative utilization of 
aliphatic sulfonates.7 Two operons, tauABCD8 and ssuEADCB,9 
have been identified which encode for distinct ABC-type 
permeases, thus promoting uptake of taurine and other 
alkanesulfonates respectively, while the TauD gene expresses for 
the protein alpha-ketoglutarate-dependent dioxygenase 
responsible for the liberation of sulphite from taurine.10 
Therefore, given our interest in developing an uptake system for 
nucleotides in bacterial cells, the synthesis of these molecules 
was also deemed important in view of their potential use as 
substrates for cellular delivery within a sulfur-based nutritional 
selection system. 
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Figure  1.  Overview  of  sulfonate‐containing  phosphoramidate  analogues  of 
thymidine. 
 
Herein, we report novel straightforward syntheses of taurine, L-
cysteic acid and a wide range of relevant sulfono-modified 
phosphoramidate nucleotide analogues (examples of TMP 
derivatives are shown in Figure 1), as well as an account of the 
efficiency with which various mesophilic and thermophilic 
microbial polymerases accept them as substrates. 
Along with the biochemical relevance, the knowledge of the 
extent to which molecular diversity can be manipulated but still 
accepted within the polymerase active site will provide 
fundamental parameters in the selection and design of new 
synthetic genetic variants.  
RESULTS AND DISCUSSION 
In an early communication, we established a synthetic approach 
to sulfonate-containing phosphoramidates Tau-dAMP 12 and L-
Cys-dAMP 13, which centred upon an EDAC-mediated coupling 
reaction between deoxyadenosine monophosphate (dAMP) and 
the relevant aminoalkylsulfonate motifs.11 However, protection 
of both sulfonic and carboxylic acids as ethyl ester groups was 
necessary to prevent formation of undesired side-products 
(Scheme 1).  
In addition, it was anticipated that in order to accomplish the 
synthesis of higher functionalized substrates, multiple selective 
protection and deprotection steps of acidic groups would be 
cumbersome, and most likely produce the novel 
phosphoramidate products in inadequate yields.  
Surprisingly, the replacement in our existing method of EDAC 
by DCC in tBuOH-H2O as coupling agent proved to be an 
alternative satisfactory procedure, even so in the presence of 
unprotected sulfonic acid functionalities. The resulting 
adenosine 5’-sulfono-phosphoramidates 12 and 13 were 
obtained in a single step with increased yields, provided that an 
excess of Et3N (5 eq.) was added to the reaction mixture in order 
to mask the charges of the sulfonic acid groups. Similarly, 
sulfono-phosphoramidates 1, 4 and 5 were isolated in good 
yields (72-77%) from thymidine monophosphate (TMP) and 
either taurine, N-methyl taurine or homo-taurine as starting 
materials (Scheme 2). This methodology was also applied to the 
preparation of L-Cys-dTMP 2 and D-Cys-dTMP 3 in the 
presence of both free sulfonic and carboxylic acids, albeit with 
reduced coupling efficiencies (25-30% yields) (Scheme 2). 
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Scheme 1. Early route towards sulfono‐phosphoramidates via ester protection of 
sulfonic acid.  
  
 
Scheme 2. Synthesis of sulfono‐phosphoramidate analogues of thimydine 1‐5 and 
adenosine 12 and 13. (a) TMP or dAMP (Na or Et3N salt), DCC, Et3N, tBuOH: H2O 
(4:1), 90 °C, 4‐6 h. 
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The same DCC-mediated protocol was also valuable to generate 
bis-sulfonate phosphoramidate 6 after coupling between the 
triethylammonium salt of TMP and the secondary amine N,N-di-
2-aminoethanesulfonate 14, afforded in turn from the Michael 
addition of taurine to sodium vinyl sulfonate (Scheme 3).  
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Scheme 3. Synthesis of thymidine phosphoramidate analogue 6. (a) NaHCO3, H2O, 
reflux, 72 h; (b) TMP, DCC, Et3N, tBuOH: H2O (4:1), 90 °C, 5.5 h. 
 
In order to provide further evidence to the geometry accepted by 
the active site,12 we decided to prepare dipeptide-like 
phosphoramidate thymidine analogues bearing various amino 
acids interconnecting the taurine unit with the amidate bond, as 
shown in Scheme 4. Peptidic bonds can be degraded in vivo by 
hydrolase enzymes releasing amino acid and taurine. 
 
The first pyrophosphate mimic of this series containing the 
neutral residue glycine, compound 16a, was accessible through 
standard coupling conditions in the presence of DCC/NHS in a 
mixture of dioxane and water, followed by Boc-removal using 
IR-120B (H+) resin.13 When taurine was reacted with a non-
neutral amino acid, the same two-steps sequence was found to be 
less rewarding, producing compound H-L-His-Tau-OH 16b in 
modest yield. All attempts to induce coupling of taurine to 
aspartic acid, however, met with failure producing only 
undesired side products (uncharacterized), with both methyl and 
benzyl featuring as protecting groups of the β-carboxyl 
functionality. Thus, compound H-L-Asp-Tau-OH 18, was 
alternatively obtained in two-steps starting from protected Z-L-
Asp (OBn)-OH and taurine, followed by hydrogenolysis.  
The final modified nucleosides were prepared under standard 
DCC coupling conditions, as outlined in Scheme 4. As the 
reaction between TMP and 18 led to the isolation of 
phosphoramidate 9 in low yield, which we believe to be due to 
the presence of a free carboxylic acid group in compound 18, we 
opted for a different route for this latter substrate. The 5’-
phosphate group was thus pre-activated by conversion into a 
better phosphoraimidazolide leaving group, which allows for 
enhanced nucleophilic attack of amines even under mild 
conditions.  
 
N-Acetic acid-2-aminoethane sulfonic acid and N-propionic 
acid-2-aminoethane sulfonic can mimic respectively 
iminodiacetic acid (IDA) and iminodipropionic acid (IDP), 
previously reported by our group as very good pyrophosphate 
mimics for DNA polymerization.14, 15  
Therefore, a series of 2’-deoxynucleoside-5’-O-[N-(alkyl acid)-
2-aminoethane sulfonic acid] phosphoramidates was prepared 
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Scheme  4.  Synthesis  of  taurine‐amino  acid  phosphoramidate  nucleoside 
analogues 7‐9. (a) (i) NHS, DCC, THF, 0 °C to r.t., 2 h, (ii) Taurine Na‐Salt, Dioxane‐
H2O  (1:1),  r.t.,  14  h;  (b)  IR‐120B  resin  (H+  form);  (c)  TMP‐Na  salt,  DCC,  Et3N, 
tBuOH:H2O (4:1), 90 °C, 4.5 h; (d) 10% Pd/C, H2, EtOH‐H2O (5:1), r.t., 16 h; (e) Et3N, 
DMF, 35 °C, 168 h. 
 
according to a three-step synthetic methodology (Scheme 5), 
starting from taurine without the need for protection of the 
sulfonic acid group. The formation of N-(ethyl acetate)-2-
aminoethane sulfonic acid 19, following the nucleophilic 
diplacement of the bromo atom in ethylbromoacetate by taurine, 
occurred only upon heating, whilst N-(ethyl acetate)-2-
aminoethane sulfonic acid 20 resulted from the Michael addition 
of taurine to ethyl acrylate at ambient temperature over seven 
days.  
 
As it might be speculated that DCC-mediated phosphoramidate 
coupling of secondary amines would prove less effective than 
that of primary amines, we thought it necessary to employ 
protected carboxylic ester derivatives in order to improve the 
reaction outcome in terms of isolated yields. Accordingly, 
reactions of TMP or dAMP thiethylammonium salts with 
secondary amine 20 were both reasonably efficient to yield 
respectively compound 25 and dAMP-analogue 26. However, to 
our surprise, the secondary amine N-(ethyl acetate)-2-
aminoethane sulfonic acid 19 failed to react under this 
conditions. Thus, for the synthesis of compounds 21-24 bearing 
all four nucleobases, we adopted the phosphoraimidazolide- 
based protocol described above, which delivered the T, A and C 
analogues 21, 22, and 24 in moderate yields (38-52%) and G 
analogue 23 in modest yield (22%). Ultimately, the deprotection 
of the ethyl ester group was carried out by treatment with a dilute 
solution of sodium hydroxide (0.4 M), and subsequent HPLC 
purification furnished the pure unprotected analogues 10-11 and 
27-30 for incorporation studies. 
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Scheme 5. Synthesis of sulfono‐phosphoramidate nucleoside analogues 10‐11 and 27‐30. (a) Ethylbromo acetate, NaHCO3, Dioxane/H2O, 70 °C, 24 h; (b) Ethyl acrylate, 
NaHCO3, EtOH‐H2O (1:1), r.t., 168 h; (c) dTMP‐Et3N salt, DCC, Et3N, tBuOH‐H2O (4:1), 90 °C, 6 h; (d) Nucleoside‐Imidazolide Na‐Salt, Et3N, DMF, 35 °C, 168 h; (e) 0.4 M 
NaOH in MeOH:H2O (4:1 v/v), r.t., 3 h. 
 
Next, Tau-dTDP β-phosphoramidate 33 was prepared according 
to the DCC-mediated phosphoramidate coupling between taurine 
and the triethylammonium salt of thymidine diphosphate 32. 
Compound 32 was derived in turn from 5’-O-tosyl derivative 
31,16 upon treatment with tris(tetra-n-butylammonium) hydrogen 
pyrophosphate, acting as a nucleophile to displace the tosyl 
group as reported by Davisson et. al.17  
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Scheme 6. Synthesis of taurine diphosphoramidate analogue 33 of thymidine. (a) 
Tris(tetra‐n‐butylammonium)  hydrogen  pyrophosphate,  CH3CN,  r.t.,  24  h;  (b) 
Taurine, DCC, Et3N,  tBuOH:H2O (4:1), 85 °C, 4.5 h. 
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Scheme 7. Synthesis of taurine triphosphoramidate analogue 35 of thymidine. (a) 
DCC, DMF, r.t., 3.5 h; (b) Taurine, MeOH/DMF, r.t., 6 h. 
 
Finally, the synthesis of Tau-dTTP γ-phosphoramidate 35 was 
accomplished through initial conversion of dTTP-Et3N salt 34 to 
thymidine-5’-trimetaphosphates by dehydration with DCC,18 
followed by ring opening of thymidine-5’-trimetaphosphate with 
an excess of taurine.  
Chain elongation experiments 
The individual competency of chemically-modified sulfono-
phosphoramidate nucleosides 1-11, 27-30, 32-33 and 35 to 
perform as active intermediates in the DNA polymerization 
reaction was assessed by comparing the activities of different 
bacterial DNA polymerases, including Therminator, Vent (exo-) 
and the Klenow fragment (exo-) of E. coli DNA Polymerase I. 
The last two mutants lacking 3´→ 5´proofreading activity 
were included in the study as preferred for affording high yield 
primer extension reactions in the presence of poor substrates, by 
suppressing simultaneous synthesis and editing. 
 
Multiple nucleotides incorporation efficiencies in primer 
extension were estimated by means of a polyacrylamide gel-
based template dependent assay, using a 5’-radiolabelled γ-33P 
DNA primer annealed in turn to T1-5 templates (Table 1). For 
each enzyme, reactions were also carried out with natural 
deoxynucleoside triphosphates (dNTP) as positive controls.  
 
Table 1. Overview of primer and templates sequences used in the 
incorporation experiments. 
Primer      P1: 5’ /5Cy5/CAGGAAACAGCTATGAC 3’  
Template T1:  3’ GTCCTTTGTCGATACTGAAAAA 5’  
Template T2:  3’ GTCCTTTGTCGATACTGTTTTTTT 5’  
Template T3:  3’ GTCCTTTGTCGATACTGGGGGG 5’  
Template T4:  3’ GTCCTTTGTCGATACTGCCCCC 5’  
Template T5:  3’ GTCCTTTGTCGATACTGCAAAA 5’ 
 
 
The first set of compounds to be examined as potential 
triphosphate mimics, were adenine sulfonate-phosphoramidates 
12-13 and thymidine analogues 1-5. Preliminary results of single 
nucleotide incorporation experiments for analogues Tau-dAMP 
12 and L-Cys-dAMP 13 had shown modest incorporation 
efficiencies into a growing DNA chain, as catalyzed by HIV-1 
reverse transcriptase11 or family C E. coli Pol III.19 However, it 
is recognized that phylogenetically distinct classes of enzymes 
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might show different substrate-specificities, despite sharing 
similar polymerization domains and mechanism. As evidence of 
a dynamic effect triggered by multiple incorporations on the 
progression of the reaction emerged in the course of previous 
studies,19 all compounds were directly subjected to elongation 
tests.  
While Vent (exo-) was not able to accept adenine analogues Tau-
dAMP 12 and L-Cys-dAMP 13 or thymidine analogues Tau-
dTMP 1, L-Cys-dTMP 2 and D-Cys-dTMP 3, 6% and 14% 
formation of the P + 1 strand was observed at 1mM (60 min) with 
Klenow (exo-) for cysteic acid-containing thymidine 
phophoramidates 2 and 3, and incorporation efficiencies with the 
same polymerase were relatively higher for adenine analogues 
12 and 13, showing 5% (P + 2) and 6% (P + 4) respectively. 
However, the thermostable polymerase Therminator could use 
all those compounds as substrates, in line with the significant 
propensity of this replicative enzyme to accept modified 
nucleotides substrates. We have observed 75% (P + 1) and 6% 
(P + 2) for 1, 68% (P + 1) and 6% (P + 2) for compound 2, 70% 
(P + 1) and 16% (P + 2) for compound 3, 18% (P+1) for 
compound 12 and complete conversion to (P + 1) strand, 58% of 
(P + 2), 28% of (P + 3), 9% of  (P + 4) and up to 2% of (P + 5) 
strand for compound 13. 
 
Within the series of analogues containing thymine as nucleobase, 
N-methyl taurine derivative N-Me-Tau-dTMP 4 showed to be 
incorporated into the primer template duplex more efficiently 
than compounds bearing taurine, D- or L-cysteic acid, with 14% 
conversion up to (P + 2) strand using Vent (60 min, 1mM) and 
17% conversion up to (P + 3) using Therminator (60 min, 1mM), 
whilst homotaurine-dTMP 5 showed only 6% and 20% 
conversion to (P + 1) strand with Vent and Therminator (60 min, 
1mM) respectively. The leaving group properties of bis-taurine 
in derivative 6 was comparable to that of N-methyl taurine, 
showing formation of 15 % of (P + 2) and 2% of (P + 3) strand 
with Vent and 21 % of (P + 2) and 3% of (P + 3) strand with 
Therminator at 60 min (1mM).  
 
The acceptance of taurine-amino acid containing derivatives 
Tau-Gly-dTMP 7, Tau-His-dTMP 8 and Tau-Asp-dTMP 9 in 
primer extension reactions by Vent (exo-) and Therminator 
polymerases was disappointing, with the exception of aspartate 
analogue 9 which showed 17% P + 1 and 2% P + 2 after 60 min 
(1mM) with Therminator. Since the individual aminoacids 
composing those structural units are proved to be good leaving 
groups, it can be concluded that the increased linear size of those 
compounds does not allow accommodation in the enzymatic 
pocket, and the results obtained for aspartate analogue 9 might 
be due to induction from the β-carboxylic functionality. 
 
  
 
Figure 2. Chain elongation efficiency of compounds 1‐11, 27‐30, 32‐33 and 35 by 
Vent (exo‐) polymerase (0.01 U.µl‐1), at 1mM conc. after 60 min. 
  
 
Figure 3. Chain elongation efficiency of compounds 1‐13, 27‐30, 32‐33 and 35 by 
Therminator polymerase (0.01 U.µl‐1), at 1mM conc. after 60 min. 
 
 
Figure 4. Chain elongation efficiency of compounds 1‐3, 10, 12‐13, 27‐30 and 35 
by Klenow fragment polymerase (exo‐) (0.05 U.µl‐1), at 1mM conc. after 60 min. 
 
The next analogues to be studied were the phosphoramidates 
derived from taurine-N-acetic acid and taurine-N-propionic acid. 
Previously, we observed a preference for incorporation for 
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purines over pyrimidines with various polymerases with the 
order A ≥ T = G > C, so we initially wished to compare thymine 
and adenine analogues. It was found that while thymidine 
analogues 10 and 11 were inserted with a comparable efficiency, 
taurine-N-acetic acid adenine nucleoside 27 was a better 
substrate for thermophilic polymerases than taurine-N-propionic 
acid adenine analogue 30. In particular, for the thymidine 
analogue 10, only 3%, 1% and up to 10% formation of P + 2 
strand in 60 min at 1mM was observed with Vent, Klenow and 
Therminator respectively, whereas the incorporation properties 
of adenine analogue 27 were better than the thymidine analogue, 
showing up to 3% P + 3 strand with Vent, 15% of P + 2 with 
Therminator and 1% of P + 4 strand with Klenow. In view of 
these observations, it was considered important to additionally 
explore the influence of the other nucleobase moieties on the 
incorporation efficiency. To this end, we synthesized and 
investigated deoxynucleoside monophosphate analogues of G 
and C nucleobases 28 and 29, modified at the 5’-position with 
the selected taurine-N-acetic acid as leaving group using Vent 
(exo-), Therminator and Klenow as polymerases. As anticipated, 
the cytidine analogue 29 showed the lowest efficiency, giving 
rise to the formation of 8% of P + 1 with Vent and Klenow and 
10 % of (P + 1) only with Therminator. Surprisingly, guanidine 
analogue 28 was added into a growing DNA chain more 
efficiently than any other nucleotide, with a final base ranking 
order G > A ≥ T > C for this set of derivatives, showing formation 
of 87% of (P + 4) and up to 5% of full length (P + 5) strand with 
Vent, up to 93% of (P + 4) with Klenow and 71% of (P + 4) and 
4% of (P + 5) strand with Therminator (Figure 5). The rationale 
behind the base-specificity of DNA polymerases is uncertain. In 
a distinct literature report, it has been shown that kinetics of 
incorporation could be affected by the diversification of the 3’-
flanking neighbouring base on the template and between pairing 
of dCTP or dTTP opposite to O6-methylguanine.20  
 
Ultimately, the elongation ability of diphosphate analogue tau-
dTDP 33 was excellent, giving up to 41% full-length chain (P + 
5) formation at 1 mM in 60 min with Vent and 9 % full length 
chain (P + 5) formation even at 0.125 mM in 15 min with 
Therminator. These findings were thought to be due to the 
presence of the diphosphate group, thus as additional evidence 
we compared compound 33 with natural 5’-thymidine 
diphosphate 32 (dTDP). Enzymatic results pointed to a slightly 
reduced incorporation efficiency for tau-dTDP in comparison to 
dTDP. Unsurprisingly, the last compound to be evaluated, Tau-
dTTP 35, was found to be as efficient as the natural substrate 
dTTP using both Therminator and Klenow although less efficient 
in the presence of Vent (exo-), showing only 22% formation of 
P + 5 strand at 1mM concentration. 
 
  
 
Figure 5. Profile of chain elongation of  the compound 28 as substrate  into  the 
P1:T4 by three different DNA polymerase; Klenow (0.05 U.µl‐1), Vent (0.01 U.µl‐
1) and Therminator (0.01 U.µl‐1).  
 
Table 2 Steady–state kinetics of single nucleotide incorporation into P1T5 by 
Klenow fragment (0.001 U.µl-1) 
Substrate Vmax [nM.min-1] Km [μM] Vmax / Km 
[x 10-3 min-1] 
dGTP 58.10 ± 3.23 0.089 ± 0.015 652.80 
Compound 28 62.55 ± 3.30 67.34 ± 11.00 0.93 
 
As the best results were seen with modified guanidine substrate 
28 and Klenow fragment (exo-), incorporation and subsequent 
extension of compound 28 into primed-template P1:T5 were 
quantitatively determined, based on the Single Complete Hit 
model, in comparison to its natural nucleoside triphosphate 
(dGTP). The steady-state kinetic analysis, the results of which 
are summarized in Table 2, indicates a Vmax value for compound 
28 1.07 fold higher than that of natural dGTP, but a KM value 758 
fold higher, with a Vmax/Km ratio of compound 28 702-fold lower 
than the natural substrate. Although the relevant nucleobase 
(adenine) and DNA enzyme (HIV-1 RT) previously employed in 
the analysis of bio-isosteres iminodiacetic acid (IDA) and 
iminodipropionic acid (IDP) were different, we can nevertheless 
conclude that the leaving group properties of taurine-N-acetic 
acid is comparable to IDA (IDA-dAMP resulted 940-fold lower 
than the natural substrate) and slightly lower than IDP (IDP-
dAMP was 83-fold lower than the natural substrate). 
CONCLUSIONS 
A novel series of modified deoxyribonucleosides bearing 
sulfonate or both carboxylate and sulfonate functional groups, 
connected through a phosphoramidate linker to the 5’-position 
were successfully prepared. Following multiple incorporation 
screening of various microbial polymerases (as reviewed in 
Figures 2, 3 and 4), the A family Klenow fragment exonuclease-
free polymerase mutant was found to be the most effective 
polymerase, giving the best elongation rates, while B family 
thermostable Therminator was confirmed as possessing the 
broader substrate-specificity. 
 
The development of new leaving groups for DNA 
polymerization can be a valuable tool for synthetic biology, for 
which the mesophylic Klenow polymerase from E. coli was 
tested and should aid the search for novel reagents able to 
perform DNA synthesis at high temperature for polymerase 
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chain reaction (PCR) for which thermostable DNA polymerases 
were tested. 
EXPERIMENTAL 
General information 
For all reactions, analytical grade solvents were used. All 
moisture-sensitive reactions were carried out under an argon or 
a nitrogen atmosphere in oven-dried glassware (135 ºC). 
Reaction temperatures are reported as bath temperatures. 
Precoated aluminum sheets (254 nm) were used for TLC. 
Compounds were visualized with UV light (λ = 254 nm). 
Products were purified by flash chromatography on ICN silica 
gel 63-200, 60 Å. All final compounds were purified by 
preparative RP-HPLC (Xbridge™ Prep C18 5μm OBD 19 x 150 
mm column) or Ion-exchange resin (Source 15 Q). All the elution 
methods use CH3CN/H2O gradients for RP-HPLC or TEAB-
H2O gradient for Ion-exchange. 1H, 13C and 31P NMR spectra 
were recorded on Bruker Avance 300 MHz, 500 MHz or 600 
MHz spectrometers. For all final compounds, 1H and 13C 
resonance assignments were made using 2D NMR correlation 
experiments (COSY, gHSQC and gHMBC). For sake of clarity, 
NMR signals of protons and carbons for sugar and base moieties 
are indicated with and without a prime, respectively. Chemical 
shifts were referenced to residual solvent signals at δ H/C 
7.26/77.00 (CDCl3), 3.31/49.10 (CD3OD) and 2.50/39.50 
(DMSO-d6) relative to TMS as internal standard. Coupling 
constants are expressed in hertz (Hz). Splitting patterns are 
reported as s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and br (broad). High resolution mass spectra were 
acquired on a quadrupole orthogonal acceleration time-of-flight 
mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA). 
Samples were infused at 3 μL/min and spectra were obtained in 
positive or negative ionization mode with a resolution of 15000 
(FWHM), using leucine enkephalin as lock mass.  
General procedure for phosphoramidates synthesis (A) 
The relevant 2’-deoxynucleoside-5’-monophosphate (1 eq.) and 
amino derivative (3-5 eq.) were suspended in a 4:1 tBuOH/H2O 
mixture (~20 mL/mmol). Triethylamine (5-10 eq.) was then 
added to the suspension to facilitate dissolution, followed by 
DCC (2-5 eq.). The reaction mixture was heated at 90 ºC for 3-6 
h. The reaction progress was monitored by TLC 
(iPrOH:H2O:Et3N/NH3 10:2:2). Upon completion, the reaction 
mixture was cooled to room temperature and the solvent was 
removed by rotary evaporation. The residue was resuspended in 
water (100 ml), washed with diethyl ether (3 x 100 ml) and the 
aqueous phase was lyophilized. The resulting crude material was 
purified by column chromatography on silica gel using the 
following gradient IPA:H2O:NH3 20:1:1, v/v/v;  15:1:1, v/v/v; 
10:1:1, v/v/v (Et3N was used instead of NH3 for carboxylic ester 
containing compounds, to avoid amide formation), to provide the 
desired nucleoside phosphoramidates as salts. Semi-preparative 
RP-HPLC (50 mmol TEAB in H2O + 2% CH3CN and 50 mmol 
TEAB in 50% H2O + 50% CH3CN) was employed for further 
purification to obtain the pure products (except for compounds 
1, 2, 3 and 8). The residues were lyophilized and freeze-dried 
repeatedly until constant mass. 
Thymidine-5’-taurine phosphoramidate ammonium salt (1). 
The ammonium salt of compound 1 was obtained as a white solid 
(0.27 g, 72%) following the general procedure (A), starting from 
2’-deoxythymidine-5’-monophosphate (TMP) disodium-salt 
(0.3 g, 0.82 mmol), taurine (0.31 g, 2.46 mmol), triethylamine 
(0.57 mL, 4.09 mmol), DCC (0.51g, 2.46 mmol) in a 4:1 
tBuOH/H2O mixture (15 mL) at 90 ºC for 3 h. 1H NMR (300 
MHz, D2O) δ = 7.69 (d, J = 1.0 Hz, 1H, H-6), 6.27 (app t, J = 7.1 
Hz, 1H, H-1’), 4.51-4.49 (m, 1H, H-3’), 4.09-4.07 (m, 1H, H-4’), 
3.94-3.91 (m, 2H, H-5’ and H-5’’), 3.17-3.10 (m, 2H, -
CH2αCH2SO3H), 2.97 (t, J = 6.6 Hz, 2H, -CH2CH2βSO3H), 2.33-
2.27 (m, 2H, H-2’ and H-2’’), 1.85 (d, J = 1.0 Hz, 3H, CH3-Thy); 
13C NMR (75 MHz, D2O) δ = 166.2 (C-4), 151.4 (C-2), 137.1 
(C-6), 111.4 (C-5), 85.3 (d, 3JC,P = 8.9 Hz, C-4’), 84.7 (C-1’), 
70.9 (C-3’), 63.8 (d, 2JC,P = 4.9 Hz, C-5’), 52.0 (d, 3JC,P = 6.3 Hz, 
-CH2CβH2SO3H), 38.4 (C-2’), 36.7 (-CαH2CH2SO3H), 11.3 
(CH3-Thy);  31P NMR (121 MHz, D2O) δ = 8.0; HRMS for 
C12H20N3O10PS [M-H]- calcd.: 428.0534, found: 428.0531. 
Thymidine-5’-(L-cysteic acid) phosphoramidate ammonium 
salt (2). The ammonium salt of compound 2 was obtained as an 
off-white solid (0.086 g, 30%) following the general procedure 
(A), starting from TMP disodium-salt (0.2 g, 0.55 mmol), L-
cysteic acid (0.31 g, 1.64 mmol), triethylamine (0.76 mL, 5.46 
mmol), DCC (0.34g, 1.64 mmol) in a 4:1 tBuOH/H2O mixture 
(14 mL) at 90 ºC for 3 h. 1H NMR (300 MHz, D2O) δ = 7.72 (d, 
J = 1.0 Hz, 1H, H-6), 6.27 (app t, J = 7.0 Hz, 1H, H-1’), 4.51-
4.49 (m, 1H, H-3’), 4.09-4.07 (m, 1H, H-4’), 3.96-3.92 (m, 2H, 
H-5’ and H-5’’), 3.87-3.83 (m, 1H, CHCO2H), 3.16 (d, J = 5.8 
Hz, 2H, CH2SO3H), 2.31-2.25 (m, 2H, H-2’ and H-2’’), 1.86 (d, 
J = 1.0 Hz, 3H, CH3-Thy); 13C NMR (75 MHz, D2O) δ = 178.6 
(CO2H), 166.3 (C-4), 151.5 (C-2), 137.1 (C-6), 111.5 (C-5), 85.5 
(d, 3JC,P = 9.3 Hz, C-4’), 84.6 (C-1’), 70.9 (C-3’), 63.7 (d, 2JC,P = 
4.8 Hz, C-5’), 54.5 (d, 3JC,P = 6.6 Hz, -CH2SO3H), 53.8 (d, 2JC,P 
= 6.1 Hz, CHCO2H), 38.2 (C-2’), 11.3 (CH3-Thy);  31P NMR 
(121 MHz, D2O) δ = 6.1; HRMS for C13H20N3O12PS [M-H]- 
calcd.: 472.0432, found: 472.0436. 
 
Thymidine-5’-(D-cysteic acid) phosphoramidate ammonium 
salt (3). The ammonium salt of compound 3 was obtained as an 
off-white solid (0.072 g, 25%) following the general procedure 
(A), starting from TMP disodium-salt (0.2 g, 0.55 mmol), D-
cysteic acid (0.31 g, 1.64 mmol), triethylamine (0.76 mL, 5.46 
mmol), DCC (0.34g, 1.64 mmol) in a 4:1 tBuOH/H2O mixture 
(14 mL) at 90 ºC for 3 h. 1H NMR (300 MHz, D2O) δ = 7.69 (d, 
J = 1.0 Hz, 1H, H-6), 6.26 (app t, J = 7.1 Hz, 1H, H-1’), 4.52-
4.49 (m, 1H, H-3’), 4.09-4.07 (m, 1H, H-4’), 3.96-3.92 (m, 2H, 
H-5’ and H-5’’), 3.86-3.82 (m, 1H, CHCO2H), 3.16 (d, J = 5.8 
Hz, 2H, CH2SO3H), 2.31-2.25 (m, 2H, H-2’ and H-2’’), 1.86 (d, 
J = 1.0 Hz, 3H, CH3-Thy); 13C NMR (75 MHz, D2O) δ = 178.0 
(d, 3JC,P = 5.1 Hz, CO2H), 166.3 (C-4), 151.5 (C-2), 137.2 (C-6), 
111.4 (C-5), 85.4 (d, 3JC,P = 9.3 Hz, C-4’), 84.7 (C-1’), 71.0 (C-
3’), 63.9 (d, 2JC,P = 5.1 Hz, C-5’), 54.5 (d, 3JC,P = 6.6 Hz, 
CH2SO3H), 53.5 (d, 2JC,P = 6.6 Hz, CHCO2H), 38.2 (C-2’), 11.3 
(CH3-Thy);  31P NMR (121 MHz, D2O) δ = 6.1; HRMS for 
ARTICLE  Journal Name 
8 | J.  Name., 2012, 00, 1‐3  This journal is © The Royal Society of Chemistry 2012 
HRMS for C13H20N3O12PS [M-H]- calcd.: 472.0432, found: 
472.0430. 
2’-Deoxyadenine-5’-taurine phosphoramidate ammonium 
salt (12).11 The ammonium salt of compound 12  was obtained 
as a white solid (0.45 g, 71%) following the general procedure 
(A), starting from dAMP (0.441 mg, 1.333 mmol), taurine (0.5 
g, 4.00 mmol), triethylamine (1.48 mL, 10.66 mmol), DCC (0.82 
g, 4.00 mmol) in a 4:1 tBuOH/H2O mixture (40 mL) at 90 ºC for 
3 h.  
2’-Deoxyadenine-5’-(L-cysteic acid) phosphoramidate 
ammonium salt (13).11 The ammonium salt of compound 13 
was obtained as a white solid (0.23 g, 32%) following the general 
procedure (A), starting from dAMP (441.5 mg, 1.333 mmol), L-
cysteic acid (338 mg, 1.999 mmol), triethylamine (1.48 mL, 
10.66 mmol), DCC (0.82 g, 4.00 mmol) in a 4:1 tBuOH/H2O 
mixture (40 mL) at 90 ºC for 3 h.  
Thymidine-5’-O-(N-methyltaurine) phosphoramidate 
triethylammonium salt (4). The triethylammonium salt of 
compound 4 was obtained as a white solid (0.39 g, 74%) 
following the general procedure (A), starting from TMP-
triethylammonium salt (0.43 g, 0.82 mmol), N-methyltaurine 
(0.57 g, 4.09 mmol), triethylamine (0.91 mL, 6.55 mmol) and 
DCC (1.01 g, 4.91 mmol) in a 4:1 tBuOH/H2O mixture (12 mL) 
at 90 ºC for 5.5 h.1H NMR (500 MHz, D2O) δ = 7.73 (s, 1H, H-
6), 6.20 (app t, J = 7.0 Hz, 1H, H-1’), 4.53-4.52 (m, 1H, H-3’), 
4.12-4.11 (m, 1H, H-4’), 3.94-3.91 (m, 2H, H-5’ and H-5’’), 
3.33-3.27 (m, 2H, CH2αCH2SO3H), 3.08 (t, J = 7.0 Hz, 2H, 
CH2CH2βSO3H), 2.58 (d, 3JH,P = 9.5 Hz , 3H, N-CH3), 2.34-2.31 
(m, 2H, H-2’ and H-2’’), 1.89 (s, 3H, CH3-Thy); 13C NMR (125 
MHz, D2O) δ = 166.0 (C-4), 151.1 (C-2), 136.7 (C-6), 111.1 (C-
5), 84.9 (d, 3JC,P = 9.1 Hz, C-4’), 84.3 (C-1’), 70.6 (C-3’), 63.5 
(d, 2JC,P = 5.3 Hz, C-5’), 48.8 (d, 3JC,P = 2.9 Hz, CH2CβH2SO3H), 
44.5 (d, 2JC,P = 4.3 Hz, CαH2CH2SO3H), 38.0 (C-2’), 33.0 (d, 
2JC,P = 3.5 Hz, N-CH3), 11.1 (CH3-Thy);  31P NMR (202 MHz, 
D2O) δ = 8.9; HRMS for C13H22N3O10PS [M-H]- calcd.: 
442.0691, found: 442.0689. 
Thymidine-5’-(3-aminopropanesulfonic acid) 
phosphoramidate triethylammonium salt (5). The 
triethylammonium salt of compound 5 was obtained as a white 
solid (0.272 g , 77%) following the general procedure (A), 
starting from TMP-disodium salt (0.2 g, 0.55 mmol), 3-
aminoethanesulfonic acid (0.23 g, 1.64 mmol), triethylamine 
(0.46 mL, 3.28 mmol) and DCC (0.45 g, 2.18 mmol) at 90 ºC for 
4 h.1H NMR (500 MHz, D2O) δ = 7.76 (s, 1H, H-6), 6.32 (app t, 
J = 7.0 Hz, 1H, H-1’), 4.55-4.53 (m, 1H, H-3’), 4.13 (br s, 1H, 
H-4’), 3.99-3.92 (m, 2H, H-5’ and H-5’’), 22.91-2.86 (m, 4H, -
CH2αCH2CH2SO3H and -CH2CH2CH2γSO3H), 2.39-2.28 (m, 2H, 
H-2’ and H-2’’), 1.89 (s, 3H, CH3-Thy), 1.87-1.81 (m, 2H, -
CH2CH2βCH2SO3H); 13C NMR (125 MHz, D2O) δ = 166.4 (C-
4), 151.5 (C-2), 136.9 (C-6), 111.1 (C-5), 85.0 (d, 3JC,P = 9.1 Hz, 
C-4’), 84.3 (C-1’), 70.7 (C-3’), 63.4 (d, 2JC,P = 4.9 Hz, C-5’), 48.2 
(-CH2CH2CγH2SO3H), 39.4 (-CαH2CH2CH2SO3H), 38.1 (C-2’), 
26.0 (d, 3JC,P = 6.8 Hz, -CH2CβH2CH2SO3H), 11.2 (CH3-Thy);  
31P NMR (202 MHz, D2O) δ = 8.5 ; HRMS for C13H22N3O10PS 
[M-H]- calcd.: 442.0690, found: 442.0668. 
N,N-2-Diaminoethanesulfonate-disodium salt (14). To a 
stirred solution of 2-aminoethane sulfonic acid (2.0 g, 16.0 
mmol) and NaHCO3 (1.34 g, 16.0 mmol) in water, was added an 
aqueous solution (25%) of sodium vinylsulfonate (6.72 mL, 15.2 
mmol). The resulting mixture was heated to reflux for 3 d. The 
reaction mixture was then cooled and the solvent was removed 
by distillation under vacuum. The remaining solid was purified 
by column chromatography on silica gel (gradient: IPA:H2O 
50:1, v/v; 20:1, v/v;  10:1, v/v) to provide compound 14 (3.58 g, 
85%) as a fluffy white solid. 1H NMR (300 MHz, D2O) δ = 3.56 
(t, J = 6.6 Hz, 2H, CH2αCH2SO3H), 3.32 (t, J = 6.6 Hz, 2H, 
CH2CH2βSO3H); 13C NMR (75 MHz, D2O) δ = 46.2 
(CH2CβH2SO3H), 43.3 (CαH2CH2SO3H); HRMS for 
C4H11NO6S2 [M-H]- calcd.: 231.9955, found: 231.9954. 
Thymidine-5’-(N,N-2-diaminoethanesulfonate) 
phosphoramidate triethylammonium salt (6). The 
triethylammonium salt of compound 6 (0.243 g, 53%) was 
obtained as a white solid following the general procedure (A), 
starting from TMP-triethylammonium salt (0.286 g, 0.55 mmol), 
compound 14 (0.76 g, 2.73 mmol), triethylamine (0.91 mL, 6.55 
mmol) and DCC (0.68 g, 3.28 mmol) in a 4:1 tBuOH/H2O 
mixture (9 mL) at 90 ºC for 5.5 h. 1H NMR (500 MHz, D2O) δ = 
7.80 (s, 1H, H-6), 6.37 (app t, J = 7.0 Hz, 1H, H-1’), 4.61-4.58 
(m, 1H, H-3’), 4.18 (br s, 1H, H-4’), 4.05-3.99 (m, 2H, H-5’ and 
H-5’’), 3.43-3.36 (m, 4H, CH2αCH2SO3H), 3.17 (t, J = 8.0 Hz, 
4H, CH2CH2βSO3H), 2.40-2.37 (m, 2H, H-2’ and H-2’’), 1.96 (s, 
3H, CH3-Thy); 13C NMR (125 MHz, D2O) δ = 166.0 (C-4), 151.2 
(C-2), 136.7 (C-6), 111.3 (C-5), 84.9 (d, 3JC,P = 9.3 Hz, C-4’), 
84.4 (C-1’), 70.6 (C-3’), 63.5 (d, 2JC,P = 5.4 Hz, C-5’), 49.5 
(CH2CβH2SO3H), 41.7 (d, 2JC,P = 4.9 Hz, CαH2CH2SO3H), 38.1 
(C-2’), 11.2 (CH3-Thy);  31P NMR (202 MHz, D2O) δ = 7.4 ; 
HRMS for C14H24N3O13PS2 [M-H]- calcd.: 536.0415, found: 
536.0418. 
General procedure for taurine-amino acid synthons synthesis 
DCC (1.1 eq.) was added to a solution of N-Boc-protected amino 
acid (1 eq.) and N-hydroxy succinimide (1.04 eq.) in dry THF 
(~4 mL/mmol) at 0 ºC, and the mixture was stirred for an 
additional 0.5 h at same temperature, then for 1.5 h at room 
temperature. The resulting DCU was filtered off, and the filtrate 
was concentrated in vacuo to afford the activated ester. The crude 
residue was then dissolved in dioxane (3 mL/mmol), and to this 
solution was added a solution of taurine sodium salt (1 eq.) in 
water (2 mL/mmol) at room temperature. The reaction mixture 
was stirred at room temperature for 14 h, followed by 
evaporation of the organic phase in vacuo. The aqueous layer 
was washed with ethyl acetate (3 x) and was then loaded on a 
column packed with IR-120B (H+ form) resin. The aqueous 
eluent was evaporated to dryness in vacuo to give a crystalline 
powder, which was recrystallized from ethanol-water to give 
pure H2N-aminoacid-Taurine-OH as a white crystalline solid. 
H-Gly-Tau-OH (16a). Compound 16a was obtained as a 
white solid (0.95 g, 91%) according to the general procedure, 
starting from DCC (1.29 g, 6.27 mmol), Boc-Gly-OH 15a (1.0 
g, 5.70 mmol), N-hydroxy succinimide (0.68 g, 5.93 mmol) in 
THF (20 mL) and taurine sodium salt (0.84 g, 5.70 mmol) in 
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dioxane-water (1:1, 30 mL). 1H NMR (300 MHz, D2O) δ = 3.82 
(s, 2H, CH2-Gly), 3.67 (t, J = 6.0 Hz, 2H, CH2αCH2SO3H), 
3.13 (t, J = 6.8 Hz, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, 
D2O) δ = 166.5 (CO-Gly), 49.1 (CH2CβH2SO3H), 40.1 (CH2-
Gly), 34.8 (CαH2CH2SO3H); HRMS for C4H10N2O4S [M-H]- 
calcd.: 181.0288, found: 181.0290. 
H-His-Tau-OH (16b). Compound 16b was obtained as a 
white solid (1.55 g, 52%) according to the general procedure, 
starting from DCC (2.58 g, 12.54 mmol), Boc-His-OH 15b 
(2.92 g, 11.40 mmol), N-hydroxy succinimide (1.36 g, 11.86 
mmol) in THF (44 mL) and taurine sodium salt (1.68 g, 11.40 
mmol) in dioxane-water (1:1, 60 mL). 1H NMR (300 MHz, 
D2O) δ = 8.05 (s, 1H, His Ar-H), 7.17 (s, 1H, His Ar-H), 4.13 
(t, J = 6.9 Hz, 1H, His-CH), 3.62-3.54 (m, 2H, 
CH2αCH2SO3H), 3.18 (d, J = 6.9 Hz, 2H, His-CH2), 3.08-2.98 
(m, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, D2O) δ = 169.6 
(CO-His), 135.4 (Ar C-His), 129.6 (Ar C-His), 116.9 (Ar C-
His), 52.9 (αC-His), 49.0 (CH2CβH2SO3H), 34.8 
(CαH2CH2SO3H), 28.0 (βC-His); HRMS for C8H14N4O4S [M-
H]- calcd.: 261.0663, found: 261.0663. 
Thymidine-5’-N-(Gly-Tau-OH)-phosphoramidate 
ammonium salt (7). The ammonium salt of compound 7 was 
obtained as a white solid (0.29 g , 68%) following the general 
procedure (A), starting from TMP-disodium salt (0.3 g, 0.82 
mmol), H-Gly-Tau-OH (0.49 g, 2.70 mmol), triethylamine (0.57 
mL, 4.09 mmol) and DCC (0.78 g, 3.78 mmol) in a 4:1 
tBuOH/H2O mixture (8 mL) at 90 ºC for 4.5 h. 1H NMR (500 
MHz, DMSO-d6) δ = 8.19 (t, J = 5.4 Hz, 1H, NH-Gly), 7.82 (d, 
J = 1.0 Hz, 1H, H-6), 6.20 (dd, J = 7.8, 6.0 Hz, 1H, H-1’), 4.27-
4.25 (m, 1H, H-3’), 3.86-3.65 (m, 1H, H-4’), 3.76-3.74 (m, 2H, 
H-5’ and H-5’’), 3.68 (br s, 1H, 3’-OH), 3.41-3.37 (m, 2H, 
CH2αCH2SO3H), 3.21 (d, J = 6.3 Hz, 2H, CH2-Gly), 3.62 (t, J = 
6.3 Hz, 2H, CH2CH2βSO3H), 2.14-2.00 (m, 2H, H-2’ and H-2’’), 
1.80 (d, J = 1 Hz, 3H, CH3-Thy); 13C NMR (125 MHz, DMSO-
d6) δ = 171.7 (d, 3JC,P = 5.1 Hz, CO-Gly), 163.9 (C-4), 150.6 (C-
2), 136.4 (C-6), 109.9 (C-5), 86.2 (d, 3JC,P = 7.8 Hz, C-4’), 83.8 
(C-1’), 71.2 (C-3’), 63.9 (d, 2JC,P = 4.9 Hz, C-5’), 50.3 
(CH2CβH2SO3H), 45.8 (CH2-Gly), 39.2 (C-2’), 35.1 
(CαH2CH2SO3H), 12.2 (CH3-Thy);  31P NMR (202 MHz, DMSO-
d6) δ = 5.1 ; HRMS for C14H23N4O11PS [M-H]- calcd.: 485.0749, 
found: 485.0750. 
Thymidine-5’-(N-His-Tau-OH)-phosphoramidate 
triethylammonium salt (8). The triethylammonium salt of 
compound 8 was obtained  as white solid (0.26 g, 41%) following 
the general procedure (A), starting from TMP-disodium salt (0.3 
g, 0.82 mmol), H-His-Tau-OH (0.97 g, 3.68 mmol), 
triethylamine (0.57 mL, 4.09 mmol) and DCC (0.85 g, 4.09 
mmol) in a 4:1 tBuOH/H2O mixture (10 mL) at 90 ºC for 4.5 h. 
1H NMR (500 MHz, D2O) δ = 7.61 (d, J =1 Hz, 1H, H-6), 7.59 
(d, J = 0.5 Hz, 1H, imidazole), 6.88 (s, 1H, imidazole), 6.32 (app 
t, J = 6.5 Hz, 1H, H-1’), 4.43-4.41 (m, 1H, H-3’), 4.04 (br s, 1H, 
H-4’), 3.81-3.75 (m, 3H, H-5’, H-5’’ and αCH-His), 3.54-3.47 
(m, 2H, CH2αCH2SO3H), 2.93-2.91 (m, 2H, βCH2-His), 2.90-
2.88 (m, 2H, CH2CH2βSO3H), 2.28-2.18 (m, 2H, H-2’ and H-
2’’), 1.84 (d, J = 1Hz, 3H, CH3); 13C NMR (125 MHz, D2O) δ = 
177.0 (CO-His), 173.9 (C-4), 157.0 (C-2), 137.9 (C-6), 136.9 (Ar 
C-His), 113.0 (C-5), 86.4 (d, 3JC,P =9.3 Hz, C-4’), 86.1 (C-1’), 
72.5 (C-3’), 65.2 (d, 2JC,P = 4.2 Hz, C-5’), 57.1 (αCH-His), 50.6 
(CH2CβH2SO3H), 40.0 (C-2’), 35.9 (CαH2CH2SO3H), 32.2 
(βCH2-His), 13.5 (CH3); 31P NMR (202 MHz, D2O) δ = 5.3; 
HRMS for C18H27N6O11PS [M-H]- calcd.: 565.1123, found: 
565.1126. 
N-Cbz-Asp(OBn)-Tau-OH (17). Compound 17 was prepared 
according to a modification of the general procedure for taurine-
amino acid synthon synthesis (ion-exchange chromatography 
was not required) starting from N-Cbz-Asp(OBn)-OH (2.5 g, 
6.99 mmol), N-hydroxy succinimide (0.84 g, 7.27 mmol), DCC 
(1.59 g, 7.70 mmol) in THF (30 mL), and taurine (0.92 g, 7.35 
mmol) and NaHCO3 (1.17 g, 13.99 mmol) in dioxane-water (1:1, 
60 mL). The crude product was resuspended in water, cooled in 
an ice-bath and acidified to pH = 5 with the addition of 1N HCl. 
The aqueous layer was then lyophilized and the crude residue 
was purified by column chromatography on silica gel (gradient: 
IPA:H2O 100:0, v/v; 30:1, v/v;  20:1, v/v) to give compound 17 
(2.89 g, 89%) as a white solid. 1H NMR (300 MHz, DMSO-d6) 
δ = 8.06 (t, J = 5.2 Hz, 1H, NH-Tau), 7.67 (d, J = 8.3 Hz, 1H, 
NH-Asp), 7.37-7.30 (m, 10H, 2 x ArH of OBn), 5.08 and 5.02 (2 
s, 2H, 2 x OCH2Ph), 4.40-4.33 (m, 1H, αCH-Asp), 3.37-3.33 (m, 
2H, CH2αCH2SO3H), 2.87-2.60 (m, 2H, βCH2-Asp), 2.56 (t, J = 
7.3 Hz, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, DMSO-d6) δ 
= 170.2 (βCO-Asp), 169.8 (αCO-Asp), 155.8 (OCONH), 136.9 
(1C of OCH2Ph), 136.1 (1C of OCH2Ph), 128.4 (Ar-C), 128.3 
(Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 65.6 (2 x 
OCH2Ph), 51.5 (αC-Asp), 50.1 (CH2CβH2SO3H), 36.4 (βC-Asp), 
35.7 (CαH2CH2SO3H); HRMS for C21H24N2O8S [M-H]- calcd.: 
463.1180, found: 463.1181. 
H-Asp-Tau-OH (18). To a stirring solution of 17 (2.89 g, 2.44 
mmol) in EtOH:H2O (5:1, 80 mL) was added 10% Pd/C (0.5 g, 
15% w/w) and the mixture was hydrogenated at atmospheric 
pressure using a balloon filled with H2 for 16 h. The catalyst was 
then removed by filtration over a pad of Celite and the filtrate 
was concentrated under reduced pressure to give compound 18 
as a white solid (1.49 g, quan.). The resulting solid was analysed 
for purity and used in the next step without any further 
purification. 1H NMR (300 MHz, D2O) δ = 4.22-4.18 (m, 1H, 
αCH-Asp), 3.66-3.60 (m, 2H, CH2αCH2SO3H), 3.11 (t, J = 6.7 
Hz, 2H, CH2CH2βSO3H), 2.84-2.64 (m, 2H, βCH2-Asp); 13C 
NMR (75 MHz, D2O) δ = 177.7 (CO2H), 170.9 (αCO-Asp), 52.5 
(αC-Asp), 51.1 (CH2CβH2SO3H), 38.5 (βC-Asp), 37.0 
(CαH2CH2SO3H); HRMS for C6H12N2O6S [M-H]- calcd.: 
239.0343, found: 239.0339. 
General procedure for phosphoramidites synthesis starting from 
2’-deoxynucleoside-5’-phosphorimidazolide sodium salts (B) 
To a stirred solution of 2’-deoxynucleoside-5’-
phosphorimidazolide sodium salt (1 eq.) and amino-acid (2.5-3.0 
eq.) in DMF, Et3N (5-10 eq.) was added and the mixture was 
stirred vigorously until total dissolution. The reaction was stirred 
at 35 °C for 7 days and then quenched by addition of water. The 
solvent was removed under reduced pressure and the resulting 
crude material was purified by column chromatography on silica 
gel (gradient: IPA/H2O/Et3N  20:1.5:0.5, v/v/v;  15:1.5:0.5, 
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v/v/v; 10:1.5:0.5, v/v/v) to provide the corresponding 
phosphoramidate as a trietylammonium salt which was further 
purified by RP-HPLC (50 mmol TEAB in 98% H2O + 2% 
CH3CN and 50 mmol TEAB in 50% H2O + 50% CH3CN) to give 
the pure product as a white solid. The isolated product was 
freeze-dried repeatedly until constant mass. 
Thymidine-5’-(Asp-Tau-OH) phosphoramidate 
triethylammonium salt (9). The triethylammonium salt of 
compound 9 was obtained as a white solid (0.17 g, 53%) 
following the general procedure (B), starting from thymidine 5’-
phosphorimidazolide-sodium salt (0.15 g, 0.38 mmol), 
compound 18 (0.229 g, 0.951 mmol) and Et3N (0.41 mL, 3.04 
mmol) in DMF (4 mL). 1H NMR (500 MHz, D2O) δ = 7.81 (s, 
1H, H-6), 6.39 (app t, J = 7.0 Hz, 1H, H-1’), 4.58-4.57 (m, 1H, 
H-3’), 4.20 (br s, 1H, H-4’), 4.03-4.01 (m, 2H, H-5’, H-5’’), 
3.84-3.79 (m, 1H, αCH-Asp), 3.64-3.60 (m, 2H, 
CH2αCH2SO3H), 3.13 (t, J = 7.0 Hz, 2H, CH2CH2βSO3H), 2.71 
(dd, J = 16.0, 5.4 Hz, 1H, βCH’-Asp), 2.60 (dd, J = 15.7, 5.1 Hz, 
1H, βCH’’-Asp), 2.40-2.37 (m, 2H, H-2’ and H-2’’), 1.95 (s, 3H, 
CH3-Thy); 13C NMR (125 MHz, D2O) δ = 177.7 (CO2H), 175.6 
(d, 3JC,P = 6.6 Hz, αCO-Asp), 166.0 (C-4), 151.2 (C-2), 136.8 (C-
6), 111.1 (C-5), 85.1 (d, 3JC,P = 9.2 Hz, C-4’), 84.4 (C-1’), 70.8 
(C-3’), 63.6 (d, 2JC,P = 4.6 Hz, C-5’), 52.6 (αCH-Asp), 49.0 
(CH2CβH2SO3H), 39.9 (d, 3JC,P = 3.5 Hz, βCH2-Asp), 38.1 (C-
2’), 34.5 (CαH2CH2SO3H), 11.1 (CH3-Thy); 31P NMR (202 MHz, 
D2O) δ = 5.8; HRMS for C16H25N4O13PS [M-H]- calcd.: 
543.0803, found: 543.0813. 
N-(Ethyl acetate)-2-aminoethanesulfonic acid (19). To a 
stirred solution of 2-aminoethane sulfonic acid (4.0 g, 31.96 
mmol) in a 1:1 dioxane/H2O mixture (80 mL), NaHCO3 (2.68 g, 
31.96 mmol) was added, followed by ethyl bromo acetate (3.75 
mL, 35.16 mmol). The reaction mixture was then heated at 70 ºC 
for 24 h. The organic layer was removed under reduced pressure 
and the remaining aqueous layer was washed with ethyl acetate 
(2 x 100 mL) and neutralized with 1N HCl. The aqueous layer 
was then concentrated under reduced pressure and the residue 
was purified by column chromatography on silica gel (gradient: 
DCM/MeOH 9:1, v/v; 8:2, v/v; 7.5:2.5, v/v) to afford compound 
19 (3.24 g, 48%) as a white solid. 1H NMR (300 MHz, D2O) δ = 
4.32 (q, J = 7.1 Hz , 2H, CO2CH2CH3), 4.05 (s, 2H, CH2CO2Et), 
3.54 (t, J = 6.8 Hz, 2H, CH2αCH2SO3H), 3.33 (t, J = 6.8 Hz, 2H, 
CH2CH2βSO3H), 1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 13C 
NMR (75 MHz, D2O) δ = 167.8, 64.1, 48.3, 47.1, 43.9, 13.8; 
HRMS for C6H13NO5S [M-H]- calcd.: 210.04416, found: 
210.0439. 
N-(Ethyl propionate)-2-aminoethanesulfonic acid (20). To a 
stirred solution of 2-aminoethane sulfonic acid (4.0 g, 31.96 
mmol) in a 1:1 EtOH/H2O mixture (80 mL), NaHCO3 (2.68 g, 
31.96 mmol) was added, followed by ethyl acrylate (3.75 mL, 
35.16 mmol). The reaction mixture was then stirred at room 
temperature for 7 days. Ethanol was removed under reduced 
pressure and the aqueous layer was washed with ethyl acetate (2 
x 100 mL) and neutralized with 1N HCl. The aqueous layer was 
then concentrated under reduced pressure and the residue was 
purified by column chromatography on silica gel (gradient: 
DCM/MeOH 9:1, v/v; 8:2, v/v; 7:3, v/v) to afford compound 20 
(4.17 g, 58%) as a white solid. 1H NMR (300 MHz, D2O) δ = 
4.15 (q, J = 7.1 Hz , 2H, CO2CH2CH3), 3.45 (t, J = 6.6 Hz, 2H, 
CH2αCH2SO3H), 3.35 (t, J = 6.5 Hz, 2H, CH2αCH2CO2Et), 3.23 
(t, J = 6.6 Hz, 2H, CH2CH2βSO3H), 2.80 (t, J = 6.5 Hz, 2H, 
CH2CH2βCO2Et), 1.20 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 13C 
NMR (75 MHz, D2O) δ = 172.1, 62.1, 46.1, 43.1, 42.9, 29.9, 
12.9; HRMS for C7H15NO5S [M-H]- calcd.: 224.0598, found: 
224.0598. 
Thymidine-5’-O-[N-(ethylacetate)-2-aminoethanesulfonic 
acid] phosphoramidate trietylammonium salt (21). The 
triethylammonium salt of compound 21 was obtained as a white 
solid (123 mg, 52%) following the general procedure (B), 
starting from thymidine-5’-phosphorimidazolide sodium salt 
(130 mg, 0.33 mmol), compound 19 (195 mg, 0.92 mmol), 
triethylamine (0.28 mL, 1.98 mmol) and DMF (4 mL). 1H NMR 
(300 MHz, D2O) δ = 7.69 (s, 1H, H-6), 6.37 (t, J = 7.1 Hz, 1H, 
H-1’), 4.58-4.54 (m, 1H, H-3’), 4.17-4.19 (m, 3H, H-4’ and 
OCH2CH3), 4.05-3.98 (m, 2H, H-5’ and H-5’’), 3.85 (d, J = 10.6 
Hz, 2H, CH2CO2Et), 3.48-3.37 (m, 2H, CH2αCH2SO3H), 3.18-
3.10 (m, 2H, CH2CH2βSO3H) (merged with Et3N), 2.37-2.32 (m, 
2H, H-2’ and H-2’’), 1.92 (s, 3H, CH3), 1.27-1.22 (m, 3H, 
OCH2CH3) (merged with Et3N); 13C NMR (75 MHz, D2O) δ = 
173.5 (d, 3JC,P = 2.4 Hz, CO2Et), 171.0 (C-4), 155.1 (C-2), 136.5 
(C-6), 111.5 (C-5), 85.0 (d, 3JC,P = 9.4 Hz, C-4’), 84.6 (C-1’), 
71.0 (C-3’), 63.9 (d, 2JC,P = 5.1 Hz, C-5’), 61.6 (OCH2CH3), 49.7 
(CH2CβH2SO3H), 48.5 (d, 2JC,P = 5.5 Hz, CH2CO2Et), 43.4 (d, 
2JC,P = 4.7 Hz, CαH2CH2SO3H), 38.5 (C-2’), 13.0 (OCH2CH3), 
11.9 (CH3); 31P NMR (121 MHz, D2O) δ = 7.1; HRMS for 
C16H26N3O12PS [M-H]- calcd.: 514.0902, found: 514.0902. 
2’-Deoxyadenosine-5’-O-[N-(ethylacetate)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (22). The triethylammonium salt of 
compound 22 was obtained as a white solid (47 mg, 38%) 
following the general procedure (B), starting from 2’-
deoxyadenosine-5’-phosphorimidazolide sodium salt (70 mg, 
0.17 mmol), compound 19 (103 mg, 0.49 mmol), triethylamine 
(0.145 mL, 1.04 mmol) and DMF (3 mL). 1H NMR (300 MHz, 
D2O) δ = 8.40 (s, 1H, H-8), 8.13 (s, 1H, H-2), 6.40 (t, J = 6.7 Hz, 
1H, H-1’), 4.72-4.68 (m, 1H, H-3’), 4.24-4.23 (m, 1H, H-4’), 
4.05-3.95 (m, 4H, H-5’,H-5’’ and OCH2CH3), 3.70 (d, J = 10.5 
Hz, 2H, CH2CO2Et), 3.41-3.28 (m, 2H, CH2αCH2SO3H), 3.11-
3.03 (m, 2H, CH2CH2βSO3H), 2.91-2.74 (m, 1H, H-2’), 2.64-
2.53 (m, 1H, H-2’’), 1.13 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C 
NMR (75 MHz, D2O) δ = 173.3 (d, 3JC,P = 2.8 Hz, CO2Et), 155.0 
(C-6), 152.2 (C-2), 148.1 (C-4), 139.4 (C-8), 118.1 (C-5), 85.7 
(d, 3JC,P = 9.3 Hz, C-4’), 83.3 (C-1’), 71.1 (C-3’), 63.8 (d, 2JC,P = 
5.2 Hz, C-5’), 61.5 (OCH2CH3), 49.7 (CH2CβH2SO3H), 48.4 (d, 
2JC,P = 5.3 Hz, CH2CO2Et), 43.4 (d, 2JC,P = 4.6 Hz, 
CαH2CH2SO3H), 38.6 (C-2’), 12.3 (OCH2CH3); 31P NMR (121 
MHz, D2O) δ = 7.2; HRMS for C10H14N5O9PS [M-H]- calcd.: 
523.1017, found: 523.1019. 
2’-Deoxyguanosine-5’-O-[N-(ethyl acetate)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (23). The triethylammonium salt of 
compound 23  was obtained as an off-white solid (58 mg, 22%) 
following the general procedure (B), starting from 2’-
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deoxyguanosine-5’-phosphorimidazolide sodium salt (150 mg, 
0.36 mmol), compound 19 (212 mg, 1.00 mmol), triethylamine 
(0.30 mL, 2.15 mmol) and DMF (4 mL). 1H NMR (300 MHz, 
D2O) δ = 7.99 (s, 1H, H-8), 6.26 (app t, J = 7.0 Hz, 1H, H-1’), 
4.65-4.63 (m, 1H, H-3’), 4.17-4.15 (m, 1H, H-4’), 4.04 (q, J = 
7.0 Hz, 2H, OCH2CH3), 3.96-3.93 (m, 2H, H-5’ and H-5’’), 3.74 
(d, J = 10.5 Hz, 2H, CH2CO2Et), 3.40-3.33 (m, 2H, 
CH2αCH2SO3H), 3.01-2.96 (m, 2H, CH2CH2βSO3H), 2.83-2.71 
(m, 1H, H-2’), 2.50-2.43 (m, 1H, H-2’’), 1.13 (t, J = 7.4 Hz, 3H, 
OCH2CH3); 13C NMR (75 MHz, D2O) δ = 173.4 (d, 3JC,P = 2.9 
Hz, CO2Et), 159.4 (C-6), 153.4 (C-2), 151.0 (C-4), 135.4 (C-8), 
117.0 (C-5),  85.3 (d, 3JC,P = 9.3 Hz, C-4’), 82.6 (C-1’), 71.2 (C-
3’), 64.0 (d, 2JC,P = 5.4 Hz, C-5’), 61.6 (OCH2CH3), 49.8 
(CH2CβH2SO3H), 48.5 (d, 2JC,P = 5.4 Hz, CH2CO2Et), 43.4 (d, 
2JC,P = 4.6 Hz, CαH2CH2SO3H), 38.4 (C-2’), 12.9 (OCH2CH3); 
31P NMR (121 MHz, D2O) δ = 7.2; HRMS for C16H25N6O11PS 
[M-H]- calcd.: 539.0967, found: 539.0969. 
2’-Deoxycytidine-5’-O-[N-(ethyl acetate)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (24). The triethylammonium salt of 
compound 24 was obtained as a white solid (130 mg, 47%) 
following the general procedure (B), starting from 2’-
deoxycytidine-5’-phosphorimidazolide sodium salt (150 mg, 
0.39 mmol), compound 19 (234 mg, 1.11 mmol), triethylamine 
(0.33 mL, 2.37 mmol) and DMF (4 mL).1H NMR (300 MHz, 
D2O) δ = 7.94 (d, J = 7.6 Hz, 1H, H-6), 6.29 (app t, J = 6.8 Hz, 
1H, H-1’), 6.08 (d, J = 7.5 Hz, 1H, H-5),  4.53-4.49 (m, 1H, H-
3’), 4.17-4.10 (m, 3H, H-4’ and OCH2CH3), 4.03-3.98 (m, 2H, 
H-5’ and H-5’’), 3.82 (d, J = 10.7 Hz, 2H, CH2CO2Et), 3.44-3.35 
(m, 2H, CH2αCH2SO3H), 3.19-3.09 (unresolved m, 2H, 
CH2CH2βSO3H, merged with Et3N), 2.43-2.21 (m, 2H, H-2’ and 
H-2’’), 1.27-1.22 (unresolved m, 3H, OCH2CH3, merged with 
Et3N); 13C NMR (75 MHz, D2O) δ = 173.4 (d, 3JC,P = 2.5 Hz, 
CO2Et), 165.8 (C-4), 157.1 (C-2), 141.2 (C-6), 96.1 (C-5), 85.6 
(C-1’), 85.4 (d, 3JC,P = 9.3 Hz, C-4’), 70.7 (C-3’), 63.7 (d, 2JC,P = 
5.2 Hz, C-5’), 61.6 (OCH2CH3), 49.7 (CH2CβH2SO3H), 48.6 (d, 
2JC,P = 5.5 Hz, CH2CO2Et), 43.4 (d, 2JC,P = 4.7 Hz, 
CαH2CH2SO3H), 39.3 (C-2’), 13.0 (OCH2CH3); 31P NMR (121 
MHz, D2O) δ = 7.2; HRMS for C15H25N4O11PS [M-H]- calcd.: 
499.0905, found: 499.0898. 
Thymidine-5’-O-[N-(ethyl propionate)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (25). The triethylammonium salt of 
compound 25 was obtained as a white solid (0.204 g, 51%) 
following the general procedure (A), starting from TMP-
triethylammonium salt (0.286 g, 0.55 mmol), compound 20 
(0.553 g, 2.46 mmol), DCC (0.563 g, 2.73 mmol), triethylamine 
(0.38 mL, 2.73 mmol) in a 4:1 tBuOH/H2O mixture (11 mL) at 
90 °C for 6 h. 1H NMR (500 MHz, D2O) δ = 7.75 (s, 1H, H-6), 
6.35 (app t, J = 7.1 Hz, 1H, H-1’), 4.58-4.56 (m, 1H, H-3’), 4.13-
4.12 (m, 1H, H-4’), 4.09-4.03 (m, 2H, OCH2CH3), 3.96-3.90 (m, 
2H, H-5’ and H-5’’), 3.42-3.35 (m, 2H, CH2αCH2SO3H), 3.34-
3.10 (m, 2H, CH2αCH2CO2Et), 3.12-3.07 (m, 2H, 
CH2CH2βSO3H), 2.63-2.51 (m, 2H, CH2CH2βCO2Et), 2.41-2.30 
(m, 2H, H-2’ and H-2’’), 1.90 (s, 3H, CH3), 1.19 (t, J = 7.1 Hz, 
3H, OCH2CH3); 13C NMR (125 MHz, D2O) δ = 174.2 (CO2Et), 
165.9 (C-4), 151.2 (C-2), 136.8 (C-6), 111.2 (C-5), 84.9 (d, 3JC,P 
= 9.4 Hz, C-4’), 84.2 (C-1’), 70.5 (C-3’), 63.3 (d, 2JC,P = 5.0 Hz, 
C-5’), 61.1 (OCH2CH3), 49.5 (CH2CβH2SO3H), 41.7 (d, 2JC,P = 
4.2 Hz, CαH2CH2SO3H), 41.5 (d, 2JC,P = 4.2 Hz, 
CαH2CH2CO2Et), 37.9 (C-2’), 33.2 (CH2CβH2CO2Et), 12.6 
(OCH2CH3), 11.1 (CH3); 31P NMR (202 MHz, D2O) δ = 7.7; 
HRMS for C16H26N3O12PS [M-H]- calcd.: 528.1058, found: 
514.1060. 
2’-Deoxyadenosine-5’-O-[N-(ethyl propionate)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (26). The triethylammonium salt of 
compound 26 was obtained as a white solid (237 mg, 53%) 
following the general procedure (A), starting from dAMP (200 
mg, 0.60 mmol), compound 20 (611.4 mg, 2.72 mmol), DCC 
(623.1 mg, 3.02 mmol), triethylamine (0.42 ml, 3.02 mmol) in a 
4:1 tBuOH/H2O mixture (12 mL) at 90 °C for 6 h. 1H NMR (300 
MHz, D2O) δ = 8.42 (s, 1H, H-8), 8.21 (s, 1H, H-2), 6.46 (app t, 
J = 6.6 Hz, 1H, H-1’), 4.74-4.69 (m, 1H, H-3’), 4.23-4.22 (m, 
1H, H-4’), 3.98-3.94 (m, 2H, OCH2CH3), 3.93-3.89 (m, 2H, H-
5’ and H-5’’), 3.32-3.23 (m, 2H, CH2αCH2SO3H), 3.18-3.12 
(unresolved m, 2H, CH2αCH2CO2Et merged with Et3N), 3.06-
2.99 (m, 2H, CH2CH2βSO3H), 2.90-2.81 (m, 1H, H-2’), 2.64-
2.55 (m, 1H, H-2’’), 2.42-2.27 (m, 2H, CH2CH2βCO2Et), 1.09 (t, 
J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (75 MHz, D2O) δ = 174.2 
(CO2Et), 155.2 (C-6), 152.4 (C-2), 148.4 (C-4), 139.5 (C-8), 
118.3 (C-5), 85.6 (d, 3JC,P = 9.3 Hz, C-4’), 83.4 (C-1’), 70.8 (C-
3’), 63.5 (d, 2JC,P = 5.0 Hz, C-5’), 61.2 (OCH2CH3), 49.9 
(CH2CβH2SO3H), 42.1 (d, 2JC,P = 4.7 Hz, CαH2CH2SO3H), 41.9 
(d, 2JC,P = 4.6 Hz, CαH2CH2CO2Et), 38.5 (C-2’), 33.5 
(CH2CβH2CO2Et), 12.8 (OCH2CH3); 31P NMR (121 MHz, D2O) 
δ = 8.1; HRMS for C17H27N6O10PS [M-H]- calcd.: 537.1174, 
found: 537.1168. 
General deprotection procedure for 2’-deoxynucleoside-5’-O-[N-
(alkyl acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salts (10-11 and 27-30) synthesis (C) 
A solution of 2’-deoxynucleoside-5’-O-[N-(ethyl alkylate)-2-
aminoethane sulfonic acid] phosphoramidate trietylammonium 
salt (1 mmol) in a 0.4M NaOH solution in MeOH/H2O (4:1v/v, 
15 mL) was stirred at room temperature for 3 h and then 1M 
TEAB buffer (8 mL) was added. All the volatiles were removed 
first by rotary evaporation (bath temp 10 °C) and then by 
lyophilization. The crude residue was purified by RP-HPLC (50 
mmol TEAB in 98% H2O + 2% CH3CN and 50 mmol TEAB in 
50% H2O + 50% CH3CN) to give pure 2’-deoxynucleoside-5’-
O-[N,N-(alkyl acid)-2-aminoethane sulfonic acid] phos-
phoramidate trietylammonium salt after the product was freeze-
dried repeatedly to constant mass. 
Thymidine-5’-O-[N-(acetic acid)-2-aminoethanesulfonic 
acid] phosphoramidate trietylammonium salt (10). The 
triethylammonium salt of compound 10 was obtained as a white 
solid (18.5 mg, 84%) following the general procedure (C), 
starting from compound 21 (20 mg, 0.028 mmol), 0.4M NaOH 
in MeOH/H2O (4:1v/v, 0.42 mL) and 1M TEAB (0.22 mL). 1H 
NMR (600 MHz, D2O) δ = 7.78 (s, 1H, H-6), 6.37 (app t, J = 7.1 
Hz, 1H, H-1’), 4.54-4.52 (m, 1H, H-3’), 4.14-4.13 (m, 1H, H-4’), 
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4.02-4.01 (m, 2H, H-5’ and H-5’’), 3.57 (d, J = 10.6 Hz, 2H, 
CH2CO2H), 3.39-3.35 (m, 2H, CH2αCH2SO3H), 3.13-3.10 (m, 
2H, CH2CH2βSO3H), 2.38-2.28 (m, 2H, H-2’ and H-2’’), 1.91 (s, 
3H, CH3); 13C NMR (150 MHz, D2O) δ = 178.6 (d, 3JC,P = 3.9 
Hz, CO2H), 166.4 (C-4), 151.6 (C-2), 137.1 (C-6), 111.6 (C-5), 
85.5 (d, 3JC,P = 9.4 Hz, C-4’), 84.7 (C-1’), 71.1 (C-3’), 63.9 (d, 
2JC,P = 5.1 Hz, C-5’), 49.7 (d, 2JC,P = 4.0 Hz, CH2CO2H), 49.1 
(CH2CβH2SO3H), 43.1 (d, 2JC,P = 3.2 Hz, CαH2CH2SO3H), 38.4 
(C-2’), 11.4 (-CH3); 31P NMR (202 MHz, D2O) δ = 7.8; HRMS 
for C16H26N3O12PS [M-H]- calcd.: 486.0589, found: 486.0591. 
2’-Deoxyadenosine-5’-O-[N-(acetic acid)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (27). The triethylammonium salt of 
compound 27 was obtained as a white solid (41 mg, 81%) 
following the general procedure (C), starting from compound 22 
(46 mg, 0.063 mmol), 0.4M NaOH in MeOH/H2O (4:1v/v, 1.0 
mL) and 1M TEAB (0.5 mL). 1H NMR (500 MHz, D2O) δ = 8.41 
(s, 1H, H-8), 8.09 (s, 1H, H-2), 6.39 (t, J = 6.8 Hz, 1H, H-1’), 
4.66-4.63 (m, 1H, H-3’), 4.21-4.20 (m, 1H, H-4’), 4.01-3.92 (m, 
2H, H-5’ and H-5’’), 3.50 (d, J = 9.0 Hz, 2H, CH2CO2H), 3.35-
3.30 (m, 2H, CH2αCH2SO3H), 3.03-3.00 (m, 2H, 
CH2CH2βSO3H), 2.80-2.75 (m, 1H, H-2’), 2.57-2.52 (m, 1H, H-
2’’); 13C NMR (125 MHz, D2O) δ = 178.2 (d, 3JC,P = 4.7 Hz, 
CO2H), 154.6 (C-6), 151.7 (C-2), 147.8 (C-4), 139.1 (C-8), 117.7 
(C-5), 85.4 (d, 3JC,P = 9.2 Hz, C-4’), 82.9 (C-1’), 70.6 (C-3’), 
63.3 (d, 2JC,P = 4.8 Hz, C-5’), 49.3 (d, 2JC,P = 3.7 Hz, CH2CO2H), 
48.7 (CH2CβH2SO3H), 42.7 (d, 2JC,P = 4.0 Hz, CαH2CH2SO3H), 
38.3 (C-2’); 31P NMR (202 MHz, D2O) δ = 8.1; HRMS for 
C10H14N5O9PS [M-H]- calcd.: 495.0705, found: 495.0703. 
2’-Deoxyguanosine-5’-O-[N-(acetic acid)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (28). The triethylammonium salt of 
compound 28 was obtained as an off-white solid (42 mg, 67%) 
following the general procedure (C), starting from compound 23 
(58 mg, 0.078 mmol), 0.4M NaOH in MeOH/H2O (4:1v/v, 1.17 
mL) and 1M TEAB (0.6 mL). 1H NMR (500 MHz, D2O) δ = 7.78 
(s, 1H, H-8), 6.25 (app t, J = 6.9 Hz, 1H, H-1’), 4.64-4.62 (m, 
1H, H-3’), 4.18-4.16 (m, 1H, H-4’), 4.00-3.95 (m, 2H, H-5’ and 
H-5’’), 3.52 (d, J = 8.8 Hz, 2H, CH2CO2H), 3.37-3.31 (m, 2H, 
CH2αCH2SO3H), 3.07-3.04 (m, 2H, CH2CH2βSO3H), 2.80-2.75 
(m, 1H, H-2’), 2.48-2.43 (m, 1H, H-2’’), 1.91 (s, 3H, CH3); 13C 
NMR (125 MHz, D2O) δ = 178.3 (d, 3JC,P = 4.8 Hz, CO2H), 
158.3 (C-6), 153.2 (C-2), 150.8 (C-4), 136.9 (C-8), 115.5 (C-5), 
85.3 (d, 3JC,P = 9.0 Hz, C-4’), 82.9 (C-1’), 70.8 (C-3’), 63.5 (d, 
2JC,P = 4.9 Hz, C-5’), 49.3 (d, 2JC,P = 3.8 Hz, CH2CO2H), 48.7 
(CH2CβH2SO3H), 42.7 (d, 2JC,P = 4.4 Hz, CαH2CH2SO3H), 37.9 
(C-2’); 31P NMR (202 MHz, D2O) δ = 8.1; HRMS for 
C14H21N6O11PS [M-H]- calcd.: 511.0654, found: 511.0651. 
2’-Deoxycytidine-5’-O-[N-(acetic acid)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (29). The triethylammonium salt of 
compound 29 was obtained as a white solid (112 mg, 78%) 
following the general procedure (C), starting from compound 24 
(130 mg, 0.185 mmol), 0.4M NaOH in MeOH/H2O (4:1v/v, 2.77 
mL) and 1M TEAB (1.4 mL). 1H NMR (500 MHz, D2O) δ = 8.00 
(d, J = 7.5 Hz, 1H, H-6), 6.37 (app t, J = 6.8 Hz, 1H, H-1’), 6.16 
(d, J = 7.5 Hz, 1H, H-5), 4.58-4.55 (m, 1H, H-3’), 4.21-4.20 (m, 
1H, H-4’), 4.09-4.07 (m, 2H, H-5’ and H-5’’), 3.60 (dd, J = 8.9, 
1.8 Hz, 2H, CH2CO2H), 3.46-3.40 (m, 2H, CH2αCH2SO3H), 
3.19-3.15 (m, 2H, CH2CH2βSO3H), 2.46-2.41 (m, 1H, H-2’), 
2.34-2.29 (m, 1H, H-2’’); 13C NMR (125 MHz, D2O) δ = 178.3 
(d, 3JC,P = 4.9 Hz, CO2H), 165.5 (C-4), 157.0 (C-2), 140.9 (C-6), 
96.0 (C-5), 85.3 (C-1’), 85.2 (d, 3JC,P = 9.2 Hz, C-4’), 70.4 (C-
3’), 63.3 (d, 2JC,P = 5.0 Hz, C-5’), 49.5 (d, 2JC,P = 3.5 Hz, 
CH2CO2H), 48.8 (CH2CβH2SO3H), 42.8 (d, 2JC,P = 4.3 Hz, 
CαH2CH2SO3H), 39.0 (C-2’); 31P NMR (202 MHz, D2O) δ = 8.1; 
HRMS for C13H21N4O11PS [M-H]- calcd.: 471.0592, found: 
471.0594. 
Thymidine-5’-O-[N-(propionic acid)-2-aminoethanesulfonic 
acid] phosphoramidate trietylammonium salt (11). The 
triethylammonium salt of compound 11 was obtained as a white 
solid (164 mg, 88%) following the general procedure (C), 
starting from compound 25 (170 mg, 0.23 mmol), 0.4M NaOH 
in MeOH/H2O (4:1v/v, 3.48 mL) and 1M TEAB (1.85 mL). 1H 
NMR (500 MHz, DMSO-d6) δ = 7.78 (d, J = 1.2 Hz, 1H, H-6), 
6.20 (dd, J =  7.9, 6.0 Hz, 1H, H-1’), 4.27-4.25 (m, 1H, H-3’), 
3.86-3.85 (m, 1H, H-4’), 3.74-3.72 (m, 2H, H-5’ and H-5’’), 
3.17-3.13 (m, 2H, CH2αCH2SO3H), 3.10-3.05 (m, 2H, 
CH2αCH2CO2H), 2.60-2.57 (m, 2H, CH2CH2βSO3H), 2.41-2.38 
(m, 2H, CH2CH2βCO2H), 2.14-2.01 (m, 2H, H-2’ and H-2’’), 
1.81 (d, J = 1.2 Hz, 3H, CH3); 13C NMR (125 MHz, DMSO-d6) 
δ = 173.7 (CO2H), 163.9 (C-4), 150.6 (C-2), 136.2 (C-6), 109.9 
(C-5), 86.1 (d, 3JC,P = 7.6 Hz, C-4’), 83.8 (C-1’), 71.1 (C-3’), 64.0 
(d, 2JC,P = 5.1 Hz, C-5’), 51.2 (CH2CβH2SO3H), 44.0 (d, 2JC,P = 
3.0 Hz, CαH2CH2SO3H), 43.0 (d, 2JC,P = 3.3 Hz, 
CαH2CH2CO2H), 39.6 (C-2’, merged with DMSO), 35.7 
(CH2CβH2CO2H), 12.1 (CH3); 31P NMR (202 MHz, DMSO-d6) 
δ = 6.3; HRMS for C16H26N3O12PS [M-H]- calcd.: 500.0745, 
found: 500.0746. 
2’-Deoxyadenosine-5’-O-[N-(propionic acid)-2-
aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (30). The triethylammonium salt of 
compound 30 was obtained as a white solid (142 mg, 86%) 
following the general procedure (C), starting from compound 26 
(150 mg, 0.202 mmol), 0.4M NaOH in MeOH/H2O (4:1v/v, 3.04 
mL) and 1M TEAB (1.50 mL). 1H NMR (500 MHz, D2O) δ = 
8.38 (s, 1H, H-8), 8.10 (s, 1H, H-2), 6.39 (app t, J = 6.6 Hz, 1H, 
H-1’), 4.69-4.67 (m, 1H, H-3’), 4.20 (br s, 1H, H-4’), 3.91-3.89 
(m, 2H, H-5’ and H-5’’), 3.30-3.24 (m, 2H, CH2αCH2SO3H), 
3.17-3.07 (m, 2H, CH2αCH2CO2H, merged with Et3N), 3.03-2.99 
(m, 2H, CH2CH2βSO3H), 2.82-2.76 (m, 1H, H-2’), 2.59-2.54 (m, 
1H, H-2’’), 2.31-2.28 (t, 2H, J = 7.9 Hz, CH2CH2βCO2H); 13C 
NMR (125 MHz, D2O) δ = 180.2 (CO2H), 154.7 (C-6), 151.8 (C-
2), 147.7 (C-4), 139.0 (C-8), 117.8 (C-5), 85.3 (d, 3JC,P = 9.2 Hz, 
C-4’), 83.0 (C-1’), 70.4 (C-3’), 63.1 (d, 2JC,P = 5.1 Hz, C-5’), 
49.5 (CH2CβH2SO3H), 43.1 (d, 2JC,P = 4.2 Hz, CαH2CH2CO2H), 
41.2 (d, 2JC,P = 4.6 Hz, CαH2CH2SO3H), 38.3 (C-2’), 36.8 
(CH2CβH2CO2H); 31P NMR (202 MHz, D2O) δ = 8.3; HRMS for 
C15H23N6O10PS [M-H]- calcd.: 509.0861, found: 509.0853. 
Thymidine-5’-diphosphosphate triethylammonium salt (32). 
To a stirred suspension of 5’-O-tosyl-thymidine 31 (0.20 g , 0.50 
mmol) in dry acetonitrile (0.5 mL) was added tris(terta-n-
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butylammonium) hydrogen phosphate (0.682 g, 0.75 mmol). The 
resulting solution was stirred at room temperature for 36 h. Upon 
reaction completion, the mixture was concentrated in vacuo, 
diluted with water (5 mL) and lyophilized. The crude product 
was purified by Source 15Q ion-exchance column 
chromatography from a gradient of 0-100% 1M TEAB solution. 
The product was freeze-dried repeatedly to constant mass, 
yielding 32 as a white triethylammonium salt solid (0.239 g, 
67%). 1H NMR (300 MHz, D2O) δ = 7.75 (d, J = 1.0 Hz, 1H, H-
6), 6.35 (app t, J = 7.0 Hz, 1H, H-1’), 4.65-4.61 (m, 1H, H-3’), 
4.18-4.14 (m, 3H, H-4’, H-5’ and H-5’’), 2.39-2.34 (m, 2H, H-
2’ and H-2’’), 1.92 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (75 MHz, 
D2O) δ = 166.2 (C-4), 151.4 (C-2), 137.0 (C-6), 111.4 (C-5), 85.1 
(d, 3JC,P = 9.1 Hz, C-4’), 84.6 (C-1’), 70.7 (C-3’), 65.0 (d, 2JC,P = 
5.5 Hz, C-5’), 38.2 (C-2’), 11.3 (CH3); 31P NMR (121 MHz, 
D2O) δ = -10.9 (d, JP,P = 20.0 Hz, β-P), -11.5 (d, JP,P = 20.0 Hz, 
α-P) HRMS for C10H16N2O11P2 [M-H]- calcd.: 401.0156, found: 
401.0155. 
Thymidine-5’-[β-N-(2-aminoethanesulfonic acid)] 
diphosphoramidate triethylammonium salt (33). The 
triethylammonium salt of compound 33 was obtained as a white 
solid (95 mg, 69%) following the general procedure (A), starting 
from compound 32 (0.12 g , 0.17 mmol), taurine (0.085 g, 0.68 
mmol), triethylamine (0.12 mL, 0.85 mmol) and DCC (0.175 g, 
0.85 mmol) in a 4:1 tBuOH/H2O mixture (4 mL) at 85 ºC for 4.5 
h.1H NMR (500 MHz, D2O) δ = 7.76 (s, 1H, H-6), 6.32 (app t, J 
= 7.0 Hz, 1H, H-1’), 4.61-4.59 (m, 1H, H-3’), 4.15-4.14 (m, 1H, 
H-4’), 4.13-4.12 (m, 2H, H-5’ and H-5’’), 3.28-3.23 (m, 2H, 
CH2αCH2SO3H), 3.07 (t, J = 7.0 Hz, 2H, CH2CH2βSO3H), 2.38-
2.27 (m, 2H, H-2’ and H-2’’), 1.89 (s, 3H, CH3); 13C NMR (125 
MHz, D2O) δ = 166.0 (C-4), 151.1 (C-2), 136.8 (C-6), 111.1 (C-
5), 84.8 (d, 3JC,P = 10.0 Hz, C-4’), 84.2 (C-1’), 70.4 (C-3’), 64.6 
(d, 2JC,P = 5.0 Hz, C-5’), 51.8 (d, 3JC,P = 7.5 Hz, CH2CβH2SO3H), 
37.9 (C-2’), 36.6 (CαH2CH2SO3H), 11.1 (CH3); 31P NMR (202 
MHz, D2O) δ = -2.6 (d, JP,P = 22.0 Hz, β-P), -11.7 (d, JP,P = 22.0 
Hz, α-P); HRMS for C12H21N3O13P2S [M-H]- calcd.: 508.0197, 
found: 508.0198. 
Thymidine-5’-[γ-N-(2-aminoethanesulfonic acid)] 
triphosphoramidate triethylammonium salt (35). DCC (0.153 
g, 0.744 mmol) was added to a stirred solution of dTTP 
triethylammonium salt 34 (0.11 g, 0.124 mmol) in dry DMF (2 
mL) under an argon atmosphere and stirred for 3.5 h at room 
temperature. The dTTP solution was then added dropwise to a 
solution of taurine (0.093 g, 0.744 mmol) in a 1:1 miture of dry 
methanol and dry DMF (16 mL) and the reaction mixture was 
left to stir for 6 h at room temperture. The reaction was then 
diluted with water (50 mL) and the precipitate was filtered off. 
The clear solution was collected and lyophilized. The crude 
residue was redissolved in 0.01M TEAB buffer and purified by 
Source-15 Q ion-exchange resin column chromatography. The 
products adhering to the column were eluted with a linear buffer 
gradient of 0 to 1 M TEAB. The desired product was isolated by 
using 0.6–0.8M TEAB and it was then further purified by HPLC 
to give compound 35 as a white triethylammonium salt solid 
(0.022 g, 18%).1H NMR (500 MHz, D2O) δ = 7.64 (s, 1H, H-6), 
6.35 (app t, J = 7.0 Hz, 1H, H-1’), 4.62-4.60 (m, 1H, H-3’), 4.18-
4.11 (m, 3H, H-4’, H-5’ and H-5’’), 3.29-3.24 (m, 2H, 
CH2αCH2SO3H), 3.00-2.96 (m, 2H, CH2CH2βSO3H), 2.34-2.26 
(m, 2H, H-2’ and H-2’’), 1.85 (s, 3H, CH3); 13C NMR (125 MHz, 
D2O) δ = 173.1 (C-4), 156.5 (C-2), 136.0 (C-6), 111.4 (C-5), 84.5 
(d, 3JC,P = 9.8 Hz, C-4’), 84.2 (C-1’), 70.3 (C-3’), 64.8 (d, 2JC,P = 
5.5 Hz, C-5’), 51.9 (d, 3JC,P = 7.2 Hz, CH2CβH2SO3H), 42.1 
(CαH2CH2SO3H), 37.9 (C-2’), 11.9 (CH3); 31P NMR (202 MHz, 
D2O) δ = -2.7 (d, JP,P = 20.6 Hz, γ-P), -12.0 (d, JP,P = 19.8 Hz, α-
P), -23.3 (app t, JP,P = 20.2 Hz, β-P); HRMS for C12H22N3O16P3S 
[M-H]- calcd.: 587.9861, found: 587.9866. 
General Protocol for DNA polymerase reaction 
The primer P1 was purchased from IDT, whilst all the templates 
T1-5 were purchased from Eurogentec. Primer oligonucleotides 
were labeled with 5’ [γ-33P]-ATP (Perkin Elmer) using T4 
polynucleotide kinase (New England Biolabs) according to the 
manufacturer’s protocol. The labeled primers were further 
purified using Illustra MicroSpin G-25 Column (GE Healthcare) 
and then annealed with the corresponding template 
oligonucleotides in a 1:2 molar ratio by heating the mixture at 75 
°C for 5 min, followed by slow cooling to room temperature. The 
DNA polymerisation mixtures contained 125 nM primer-
template complex, 1X reaction buffer (supplied with the 
enzyme), different concentrations of building blocks (125 µM, 
500 µM and 1 mM) and 0.01 U.µl-1 Therminator, 0.01 U.µl-1 
Vent (-exo) or 0.05 U.µl-1 Klenow (-exo) polymerases (New 
England Biolabs). The reaction was performed either at 37 °C 
(mesophilic polymerase) or at 75 °C (thermophilic polymerases) 
and aliquots were taken after 15, 30 and 60 min. In the control 
reaction, 50 µM of the corresponding natural deoxynucleoside 
triphosphate was used. All the polymerase reactions were 
quenched by addition of a double volume of gel loading buffer 
(90% formamide, 50mM EDTA, 0.05% bromophenol blue and 
0.05% xylene cyanol). Samples were heated either at 75 °C 
(mesophilic polymerase) or at 90 °C (thermophilic polymerases) 
for 5 min prior to separation on a 0.4mm 20% denaturing 
polyacrylamide gel. The bands were then visualized using 
phosphorimaging (Perkin Elmer).  
Steady-state kinetics of single nucleotide incorporation 
 Primer 5’ /5Cy5/CAGGAAACAGCTATGAC 3’ was annealed 
with template 3’ GTCCTTTGTCGATACTGCAAAA 5’ in a 1:2 
molar ratio by heating the mixture at 75 °C for 5 min, followed 
by slow cooling to room temperature. A series of reactions with 
different enzyme concentrations and different time points were 
performed to obtain the optimum conditions satisfying the 
‘single completed hit’ principle21. The final DNA polymerisation 
mixtures each contained 125 nM primer-template complex, 1X 
reaction buffer (supplied with the enzyme), building blocks (for 
modified building blocks the concentration ranged between 15 
µM and 1 mM, whilst for natural nucleoside triphosphates the 
concentration ranged between 25 nM and 2 µM) and 0.001 U.µl-
1 Klenow fragment (New England Biolabs). The reactions were 
performed at 37 °C and aliquots were taken after 30 seconds. All 
polymerase reactions were quenched by adding a double volume 
of gel loading buffer (90 % formamide, 50 mM EDTA and 
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0.05% bromophenol blue) and heated at 90 °C for 5 min. The 
samples were separated on a 1 mm 15% denaturing 
polyacrylamide gel and gel bands were visualized using Ettan 
DIGE Imager (GE Healthcare). The gel bands were then 
quantified using ImageQuant TL 1D version 7.0 (GE Healthcare) 
and the kinetics parameters (VMAX and KM) were determined by 
fitting the data to a non-linear Michaelis–Menten regression 
using GraphPad Prism Software version 5.0. 
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